This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
An article by Bateman and Carlton (The Journal, Oct. 20, 1956, page 701) on the use of triethylenethiophosphoramide ( thio-TEPA ) presents data suggesting that this drug has unusual properties in controlling primary and disseminated carcinoma of the breast. These authors maintain it is of special value when injected directly into the tumor site, although claims are also made of good effects on cerebral, osseous, and pulmonary metastases after systemic administration.Conclusions as to the value of any therapeutic procedure in patients with disseminated cancer of the breast are usually fraught with error because of the variability of the natural course of the disease, variations in the selection and size of clinical samples, and the difficulty in measuring objective regression of the disease. Even when undisputed tumor regression does occur, it is necessary to determine if regression is due to the agent under investigation or to ancillary therapy, or
Taylor SG. BREAST CARCINOMA AND TRIETHYLENE-THIOPHOSPHORAMIDE. JAMA. 1957;164(4):486–487. doi:10.1001/jama.1957.02980040126028
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: